BRPI0909374A2 - métodos para tratar desordens fibróticas - Google Patents

métodos para tratar desordens fibróticas

Info

Publication number
BRPI0909374A2
BRPI0909374A2 BRPI0909374A BRPI0909374A BRPI0909374A2 BR PI0909374 A2 BRPI0909374 A2 BR PI0909374A2 BR PI0909374 A BRPI0909374 A BR PI0909374A BR PI0909374 A BRPI0909374 A BR PI0909374A BR PI0909374 A2 BRPI0909374 A2 BR PI0909374A2
Authority
BR
Brazil
Prior art keywords
methods
fibrotic disorders
treat fibrotic
treat
disorders
Prior art date
Application number
BRPI0909374A
Other languages
English (en)
Inventor
David Sherris
Original Assignee
Paloma Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Paloma Pharmaceuticals Inc filed Critical Paloma Pharmaceuticals Inc
Publication of BRPI0909374A2 publication Critical patent/BRPI0909374A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Pyrane Compounds (AREA)
BRPI0909374A 2008-03-25 2009-03-25 métodos para tratar desordens fibróticas BRPI0909374A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3914608P 2008-03-25 2008-03-25
PCT/US2009/038285 WO2009120799A2 (en) 2008-03-25 2009-03-25 Methods of treating fibrotic disorders

Publications (1)

Publication Number Publication Date
BRPI0909374A2 true BRPI0909374A2 (pt) 2015-10-06

Family

ID=41114682

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0909374A BRPI0909374A2 (pt) 2008-03-25 2009-03-25 métodos para tratar desordens fibróticas

Country Status (9)

Country Link
US (1) US20110021618A1 (pt)
EP (1) EP2271334B1 (pt)
JP (2) JP5679582B2 (pt)
CN (1) CN102046165A (pt)
AU (1) AU2009228303B2 (pt)
BR (1) BRPI0909374A2 (pt)
CA (1) CA2719853A1 (pt)
MX (1) MX2010010431A (pt)
WO (1) WO2009120799A2 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9381187B2 (en) 2011-02-16 2016-07-05 Paloma Pharmaceuticals, Inc. Radiation countermeasure agents
PT2866804T (pt) * 2012-06-27 2023-12-18 Amazentis Sa Melhoria da autofagia ou aumento da longevidade por administração de urolitinas ou seus precursores
EP3592425A1 (en) 2017-03-08 2020-01-15 Amazentis SA Methods for improving mitophagy in subjects
CA3136242A1 (en) * 2019-03-13 2020-09-17 St. Jude Children's Research Hospital, Inc. Small molecules that bind cyclin-dependent kinase inhibitor 1b (p27kip1)

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5576873A (en) * 1978-11-30 1980-06-10 Kaken Pharmaceut Co Ltd Coumarin derivative, its preparation, and antiallergic drugs containing it as active constituent
US4248861A (en) * 1979-02-21 1981-02-03 Schutt Steven R Skin treatment methods
US4299826A (en) * 1979-10-12 1981-11-10 The Procter & Gamble Company Anti-acne composition
US5851785A (en) * 1992-02-04 1998-12-22 Kyowa Medex Co., Ltd. Method of quantitative determination of substances using coumarin derivatives
US5690944A (en) * 1994-12-20 1997-11-25 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Cosmetic compositions containing lactate dehydrogenase inhibitors
GB2304047A (en) * 1995-08-09 1997-03-12 Univ Manchester Pharmaceutical compositions containing cytokines
US20020025316A1 (en) * 1995-08-18 2002-02-28 Ferguson Mark Williams James Pharmaceutical composition containing inhibitors of interferon-gamma
US6011036A (en) * 1997-04-15 2000-01-04 Dr. Reddy's Research Foundation Heterocyclic compounds having antidiabetic hypolipidemic antihypertensive properties process for their preparation and pharmaceutical compositions containing them
FR2768736B1 (fr) * 1997-09-24 2000-05-26 Roussel Uclaf Nouveaux composes tricycliques, leur procede de preparation et les intermediaires de ce procede, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant
ATE213939T1 (de) * 1997-11-25 2002-03-15 Yamanouchi Europ Bv Verwendung eines gemischs aus einem diol und einer alpha-hydroxysäure zur behandlung hyperkeratotischer hauterkrankungen
US6632961B1 (en) * 1998-05-22 2003-10-14 Abbott Laboratories Antiangiogenic drug to treat cancer, arthritis and retinopathy
US20070179135A1 (en) * 2006-01-05 2007-08-02 Travis Craig R Cannabinoid derivatives
HUP0203437A3 (en) * 1999-03-22 2003-07-28 Immugen Pharmaceuticals Inc So Use of resorcinol derivatives for producing pharmaceutical compositions for treatment of immune diseases
US20080108647A1 (en) * 1999-03-22 2008-05-08 Travis Craig R Treatment of HIV and diseases of immune dysregulation
US8586767B2 (en) * 1999-03-22 2013-11-19 Craig Rick Travis Method for treatment of HIV and diseases of immune dysregulation
US6566560B2 (en) * 1999-03-22 2003-05-20 Immugen Pharmaceuticals, Inc. Resorcinolic compounds
US6566395B1 (en) * 1999-05-25 2003-05-20 Biomedicines, Inc. Methods of treating proliferative disorders
US6541510B2 (en) * 2000-09-28 2003-04-01 Immugen Pharmaceuticals, Inc. Antiviral methods and compounds
US20020137802A1 (en) * 2000-09-28 2002-09-26 Travis Craig R. Methods and compounds for inhibiting eicosanoid metabolism and platelet aggregation
US20020119914A1 (en) * 2000-12-26 2002-08-29 Deguang Zhu New uses of insulin and pancreatin
US6632835B2 (en) * 2001-02-22 2003-10-14 Nanodesign Inc. Dibenzo[c]chromen-6-one derivatives as anti-cancer agents
RU2003132706A (ru) * 2001-04-06 2005-04-20 Байокрист Фармасьютикалз, Инк. (Us) Диариловые соединения в качестве ингибиторов сериновых протеаз
CN1652766A (zh) * 2002-03-18 2005-08-10 免疫力药品有限公司 间苯二酚和大麻素的局部制剂及其施用方法
EP1537090A1 (en) * 2002-08-13 2005-06-08 Warner-Lambert Company Llc Chromone derivatives as matrix metalloproteinase inhibitors
TWI323662B (en) * 2002-11-15 2010-04-21 Telik Inc Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy
EP1618101B1 (de) * 2003-02-25 2017-12-20 Merck Patent GmbH Benzochromenderivate
WO2004092154A1 (en) * 2003-04-03 2004-10-28 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
CN1809552A (zh) * 2003-05-20 2006-07-26 田纳西大学研究基金会 大麻素衍生物、其制备方法和用途
US7456214B2 (en) * 2004-05-03 2008-11-25 Baylor University Chromene-containing compounds with anti-tubulin and vascular targeting activity
US20060257337A1 (en) * 2005-04-28 2006-11-16 David Sherris Compositions and methods to treat skin diseases characterized by cellular proliferation and angiogenesis
CA2643579C (en) * 2006-02-28 2018-05-15 Paloma Pharmaceuticals, Inc. Compositions and methods to treat diseases characterized by cellular proliferation and angiogenesis
US8324405B2 (en) * 2008-02-05 2012-12-04 Fibrogen, Inc. Chromene derivatives and use thereof as HIF hydroxylase activity inhibitors

Also Published As

Publication number Publication date
US20110021618A1 (en) 2011-01-27
CN102046165A (zh) 2011-05-04
CA2719853A1 (en) 2009-10-01
AU2009228303A1 (en) 2009-10-01
WO2009120799A2 (en) 2009-10-01
JP2011515488A (ja) 2011-05-19
JP5679582B2 (ja) 2015-03-04
AU2009228303B2 (en) 2015-08-13
JP2015038092A (ja) 2015-02-26
EP2271334B1 (en) 2015-08-12
MX2010010431A (es) 2010-11-25
WO2009120799A9 (en) 2010-01-21
EP2271334A2 (en) 2011-01-12
EP2271334A4 (en) 2011-08-10

Similar Documents

Publication Publication Date Title
BRPI0915476A2 (pt) dispositivo para tratar problemas respiratórios
BR112012011730A2 (pt) tratamentos para distúrbios gastrointestinais
BRPI0919882A2 (pt) métodos para avaliar padrões de rna
BRPI0914614A2 (pt) 2-arilaminoquinazolinas para tratar doenças proliferativas
BRPI0911426A2 (pt) ferramentas terapêuticas e métodos para tratar cegueira
BRPI1011226A2 (pt) métodos para tratar condições relacionadas ao cabelo
BRPI0919127A2 (pt) métodos para tratamento de água
HK1155374A1 (zh) 用於治療炎性疾病和纖維變性疾病的化合物和方法
BRPI1015233A2 (pt) métodos para tratar ou prevenir a fadiga
BRPI1013878A2 (pt) método para tratar distúrbios metabólicos, e, composto
BRPI0817547A2 (pt) Método para realizar pirólise
BRPI0819050A2 (pt) Método para desidroaromatizar metano
BR112012002269A2 (pt) implemento para tratar superfície
BRPI0908715A2 (pt) métodos para tratamento da psoríase
BRPI1008253A2 (pt) Metoso para tratar biomassa
BR112013008528A2 (pt) métodos para tratar psoríase
BRPI1013361A2 (pt) método para evitar e tratar hipermeabilidade.
DOP2009000005A (es) Metodos para tratar y limitar trastornos fibroticos y queloides
BRPI0819633A2 (pt) Métodos para produzir poliolefinas
BRPI1015444A2 (pt) método para produzir (+)-zizaeno
BRPI0810091A2 (pt) Agentes fugicidas tópicos para tratar distúrbios ungueais
BR112012006437A2 (pt) composições e métodos para tratamento do diabetes e outros distúrbios
BRPI0921679A2 (pt) composto útil para tratar celulite
BR112014013694A2 (pt) método para tratar uma doença, e, kit
BRPI0923909A2 (pt) Método para tratar uma ou mais hastes de cabelo

Legal Events

Date Code Title Description
B08F Application fees: dismissal - article 86 of industrial property law
B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)